Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT05372887
Other study ID # TNX-CY-P308
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date October 14, 2022
Est. completion date November 8, 2022

Study information

Verified date December 2023
Source Tonix Pharmaceuticals, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, fixed-dose study that will investigate the efficacy and safety of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets)-a sublingual formulation of cyclobenzaprine. Following successful screening and randomization, eligible patients will have a telephonic visit at week 2 and then return regularly to the study clinic for monthly visits for assessments of efficacy and safety.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date November 8, 2022
Est. primary completion date November 8, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Male or female between 18 and 75 years of age, at the time of signing ICF, inclusive. - Diagnosed with current (past month) PTSD as determined by the MINI 7.0.2 Module H (PTSD). - Index trauma(s) resulting in PTSD must meet DSM-5 Criterion A for PTSD as described in the CAPS 5, must have occurred within 9 years of Screening Visit 1, and must have occurred when the participant was =18 years of age. - Willing and able to withdraw and refrain from opioids for the course of the study. - Willing to refrain from use of all other formulations of cyclobenzaprine for the course of the study. - Willing and able to refrain from antidepressants and other excluded medications. - Capable of reading and understanding English and able to provide written informed consent to participate. - Willing to comply with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol. - If female, either not of childbearing potential or practicing a medically acceptable method of birth control throughout the study. - Body mass index (BMI) within the range 17.5 - 35 kg/m^2 (inclusive). Exclusion Criteria: - Current or ongoing exposure to the trauma that resulted in the PTSD (ie, non-work-related trauma such as ongoing domestic abuse). - Increased risk of suicide, based on the investigator's judgment that is of a severity that is not appropriate for outpatient management, or that warrants additional therapy excluded by the protocol. - Significant (eg, moderate or severe) comorbid traumatic brain injury (TBI) by history. - Severe depressive symptoms at screening or baseline. - Clinically significant laboratory abnormalities based on screening laboratory tests and/or medical history in the investigator's opinion. - Use of antidepressant medication within 2 months of baseline. - Female participants who are pregnant or lactating. - History of serotonin syndrome, severe allergic reaction or bronchospasm or known hypersensitivity to cyclobenzaprine or the excipients in TNX-102 SL or placebo formulations. - Seizure disorder. - Current moderate or severe sleep apnea not well controlled by positive airway pressure (PAP) or oral (mouthpiece) devices. - Has received any other investigational drug within 90 days before Screening or has taken cyclobenzaprine within 21 days of the Randomization visit. - Previous participation in any other study with TNX-102 SL. - Family member of investigative staff.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TNX-102 SL
Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks
Placebo
Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 1 for 12 weeks

Locations

Country Name City State
Kenya Aga Khan University Clinical Research Unit Nairobi
Kenya Centre for Clinical Research at KEMRI-Nairobi Nairobi
Kenya Moi University Clinical Research Centre Nairobi

Sponsors (1)

Lead Sponsor Collaborator
Tonix Pharmaceuticals, Inc.

Country where clinical trial is conducted

Kenya, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change from baseline in the total Clinician Administered PTSD Scale (CAPS-5) for DSM-5 at Week 12. To evaluate the efficacy of the TNX-102 SL (cyclobenzaprine HCl sublingual tablets) using the Clinician Administered PTSD Scale for Diagnostic and Statistical Manual of Mental Disorders, fifth edition (CAPS-5) total symptom severity score in a 12-week study. Day 1, Week 4, Week 12
Secondary Clinical Global Impression - Severity change from Baseline to Week 12 CGI-S to assess global severity change from baseline to Week 12 Day 1, Week 4, Week 8, Week 12
Secondary Change from baseline in the disruption of psychosocial functioning assessed using the Sheehan Disability Scale (SDS) after 12 weeks of treatment. SDS to assess psychosocial functioning change from baseline to Week 12 Day 1, Week 4, Week 8, Week 12
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03962504 - Written Exposure Therapy Versus Prolonged Exposure: a Non-inferiority Trial N/A
Completed NCT01995123 - Behavioral Activation for Smoking Cessation in PTSD N/A
Not yet recruiting NCT06278922 - Evaluating Signs of Safety: A Deaf-Accessible Therapy Toolkit for AUD and Trauma N/A
Completed NCT04597450 - Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD) Phase 1
Completed NCT03593772 - Mission Reconnect- Delivering a Mobile and Web Based Self Directed Complementary And Integrative Health Program to Veterans and Their Partners to Manage Pain and PTSD N/A
Completed NCT03429166 - Connecting Women to Care: Home-based Psychotherapy for Women With MST Living in Rural Areas N/A
Recruiting NCT04317820 - Deep Brain Reorienting in Post-traumatic Stress Disorder N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT03504722 - Evaluating the Feasibility of RESCUE: An Adjunctive HAI-Based Intervention for Veterans With PTSD N/A
Completed NCT04305353 - Intensive Care Unit (ICU) Diary Project N/A
Completed NCT03113890 - McLean and Genomind Prospective Study N/A
Withdrawn NCT05173831 - Study of Feasibility and Safety of MDMA-Assisted Group Therapy for the Treatment of PTSD in Veterans Phase 2
Not yet recruiting NCT04056767 - Changes in Digital Phenotype During PE Therapy
Withdrawn NCT03924297 - Chilipad for Sleep and Symptoms of PTSD N/A
Completed NCT03158558 - Intensive Weekend Retreat Multi-Couple Group Therapy for PTSD N/A
Completed NCT03343028 - Biomarker Establishment for Superior Treatment of PTSD
Withdrawn NCT03216356 - Effect of D-cycloserine on a Short Imagery Rescripting Intervention for Subclinical PTSD Phase 2/Phase 3
Completed NCT02370173 - A Non-Pharmacological Method for Enhancing Sleep in PTSD N/A
Completed NCT01911585 - Efficacy of 60-minute Versus 90-minute Sessions in Treating PTSD Using Prolonged Exposure N/A
Withdrawn NCT01957371 - Mindful Yoga Therapy for Veterans With PTSD and Pain N/A